Prospects for oral replicating adenovirus-vectored vaccines

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Orally delivered replicating adenovirus (Ad) vaccines have been used for decades to prevent adenovirus serotype 4 and 7 respiratory illness in military recruits, demonstrating exemplary safety and high efficacy. That experience suggests that oral administration of live recombinant Ads (rAds) holds promise for immunization against other infectious diseases, including those that have been refractory to traditional vaccination methods. Live rAds can express intact antigens from free-standing transgenes during replication in infected cells. Alternatively, antigenic epitopes can be displayed on the rAd capsid itself, allowing presentation of the epitope to the immune system both prior to and during replication of the virus. Such capsid-display rAds offer a novel vaccine approach that could be used either independently of or in combination with transgene expression strategies to provide a new tool in the search for protection from infectious disease.

Original languageEnglish (US)
Pages (from-to)3236-3243
Number of pages8
Issue number32
StatePublished - 2013


  • Capsid-display
  • Hexon
  • Oral administration
  • Replicating adenovirus vectors
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Prospects for oral replicating adenovirus-vectored vaccines'. Together they form a unique fingerprint.

Cite this